Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 2003 implications for cancer control

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 591-599

  Tracey, Elizabeth A ^a,d   Roder, David M ^b   Francis, Jane ^b   Zorbas, Helen M ^b   Hacker, Neville F ^c   Bishop, James F ^a  

^a New South Wales Cancer Registry   (Australia)

^b National Breast Cancer Centre   (Australia)

^c ROYAL HOSPITAL FOR WOMEN   (Australia)

^d Cancer Institute New South Wales   (Australia)

Author keywords

Histological type; Ovarian cancer; Stage; Survival

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SOCIOECONOMICS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; NEW SOUTH WALES; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SOCIOECONOMIC FACTORS;

EID: 67651068018     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3a436     Document Type: Article

References (44)

1. Tracey EA, Chen S, Baker D, et al. Cancer in New South Wales: Incidence and Mortality 2004. Sydney: Cancer Institute NSW; 2006.
2. Australian Institute of Health and Welfare & National Breast Cancer Centre. Ovarian Cancer in Australia: An Overview, 2006. Canberra: Australian Institute of Health and Welfare; 2006. Cancer series no. 35. Cat. no. CAN 30.
3. Adami H-O, Hunter D, Trichopoulos D, eds. Textbook of Cancer Epidemiology. New York: Oxford University Press; 2002:378-399.
4. Ries LAG, Harkins D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
5. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109:221-227.
6. Tingulstad, Hagen B, Skjeldestad FE, et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93:448-452.
7. Davies AP, Jacobs I, Woolas R, et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol. 1993;100:927-931.
8. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20: 1248-1259.
9. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103-108.
10. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) Gynecol Oncol. 2006;103:559-564.
11. Averette HE, Janicek MF, Menck HR. The national cancer data base report on ovarian cancer, American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1096-1103.
12. Australian Cancer Network & National Breast Cancer Centre. Clinical Practice Guidelines for the Management of Women With Epithelial Ovarian Cancer. Sydney: National Breast Cancer Centre; 2004.
13. Sobin LH, Wittekind CL, eds. TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons; 2002.
14. Australian Bureau of Statistics. 1996 Census of Population and Housing. Socio-Economic Indexes for Areas. Canberra: Australian Bureau of Statistics; 1998.
15. Department of Health and Aged Care and the University of Adelaide. Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA). Canberra: Commonwealth of Australia; 1999. Occasional papers: new series no. 6.
16. Parkin DM, Shanmugarathnam K, Sobin L, et al. Histological Groups for Comparative Studies. IARC Technical Report no. 31. Lyon: IARC; 1998.
17. SAS/STAT Software, Version 9.1. Cary, NC: SAS Institute Inc; 2003.
18. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford: Blackwell Scientific Publications; 1987.
19. Tracey EA, Bishop J, Roder D, et al. Comparison of cause-specific and relative survival for major cancer sites in NSW. Asia Pac J Clin Oncol. 2006;2:A70.
20. South Australian Cancer Registry. Epidemiology of Cancer in South Australia. Incidence, Mortality and Survival, 1977 to 1996. Incidence and Mortality, 1996. Adelaide: Openbook Publishers; 1997:21-28.
21. Bray F, Loos AH, Toqnazzo S, et al. Ovarian cancer in Europe: crosssectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer. 2005;113:977-990.
22. Bjorge T, England A, Hansen S, et al. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. Int J Cancer. 1997;71:780-786.
23. Ries LAG, Miller BA, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1994. NIH Publication 94-2789.
24. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172-180.
25. Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynaecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106:589-598.
26. Grant PT, Beischer NA, Planner RS. The treatment of gynaecological malignancy in a general public hospital. Med J Aust. 1992;157:378-380.
27. McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 1993;71:628-633.
28. Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynaecologic oncologist? Gynecol Oncol. 1992;47:223-227.
29. Junor EJ, Hole DJ, McNulty L, et al. Specialist gynaecologists and survival outcomes in ovarian cancer: a Scottish national study of 1866 patients. Brit J Obstet Gynaecol. 1999;106:1130-1136.
30. Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002;99: 1008-1013.
31. Vernooij F, Heintz P, Witteveen E, et al. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105: 801-812. E-pub April 12, 2007.
32. Tracey E, Baker D, Chen W, et al. Cancer in New South Wales: Incidence, Mortality and Prevalence, 2005. Sydney: Cancer Institute NSW; 2007.
33. Ries LAG, Harkins D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2003. Bethesda MD: National Cancer Institute; 2006.
34. Jemal A, Siege R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
35. South Australian Cancer Registry. Epidemiology of Cancer in South Australia. Incidence, Mortality and Survival, 1977 to 1999. Incidence and Mortality, 1999. Adelaide: Openbook Publishers; 2000:158-165.
36. Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer. 2007;109: 2031-2042.
37. Osmanaoaoglu MA, Kadioglu S, Osmanaoaoglu S, et al. The relationship of p53 and DNA ploidy variables in patients with ovarian carcinoma. Geburtshilfe Frauenheilkd. 2005;65:778-785.
38. Kazlauskaite N, Koneiute K. Ovarian cancer stage I: DNA ploidy and relations with clinico pathological features. Acta Med Litu. 2005; 12:60-64.
39. Cervantes A. Prognostic factors in advanced ovarian cancer. Int J Gynecol Cancer 1997;7:4-8.
40. Tingulstad S, Skjeldestad FE, Halvorsen TB, et al. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003;101:885-891.
41. English D, Farrugia H, Thursfield, et al. Cancer Survival 2007. Melbourne: Cancer Council Victoria; 2007.
42. Lataifeh I, Marsden D, Robertson D, et al. Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 2005;45: 211-214.
43. Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. Br J Cancer. 2001;85:944-952.
44. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer. 2006;94:904-913.